Learn More
Cancers arise owing to mutations in a subset of genes that confer growth advantage. The availability of the human genome sequence led us to propose that systematic resequencing of cancer genomes for mutations would lead to the discovery of many additional cancer genes. Here we report more than 1,000 somatic mutations found in 274 megabases (Mb) of DNA(More)
The panel of 60 human cancer cell lines (the NCI-60) assembled by the National Cancer Institute for anticancer drug discovery is a widely used resource. The NCI-60 has been characterized pharmacologically and at the molecular level more extensively than any other set of cell lines. However, no systematic mutation analysis of genes causally implicated in(More)
Malignant gliomas have a very poor prognosis. The current standard of care for these cancers consists of extended adjuvant treatment with the alkylating agent temozolomide after surgical resection and radiotherapy. Although a statistically significant increase in survival has been reported with this regimen, nearly all gliomas recur and become insensitive(More)
Established BLOCKIN BLOCKIN and BLOCKIN BLOCKIN emerging BLOCKIN BLOCKIN European BLOCKIN BLOCKIN research BLOCKIN BLOCKIN infrastructures BLOCKIN BLOCKIN are BLOCKIN BLOCKIN holding BLOCKIN BLOCKIN or BLOCKIN BLOCKIN will BLOCKIN BLOCKIN in BLOCKIN BLOCKIN the BLOCKIN BLOCKIN near BLOCKIN BLOCKIN future hold immense quantities of data. Power lies not only(More)
  • 1